CIMAher

A A A

CIMAB S.A., 206 Street, No. 1926, ATABEY, Playa, Ciudad de La Habana, CUBA
Tel.: (53 7) 2725162, 2725163, 2715057
Fax: (53 7) 2733509
Email: cimab@cim.sld.cu

CIMAher (nimotuzumab) is a humanized monoclonal antibody that recognized the Epidermal Growth Factor receptor with a high affinity for the Cancer treatment.

CIMAher for PROFESSIONALS

CIMAher for PATIENTS

Product description

Therapeutic indications

Sanitary Registrations

Clinical Studies

Publications

Warning about possible adverse reactions
Contact information by countries
Links to usefull information

What is CIMAher?
CIMAher (nimotuzumab) is a humanized monoclonal antibody that reacts with the Epidermal Growth Factor receptor (EGFR) with a high affinity, blocking the interaction between the Epidermal Growth Factor (EGF) and its receptor.
◄ Image of a monoclonal antibody.
How works CIMAher?
The EGF and their receptor play a very important role in cells growth in the organism, in ... (Read more)

News

National Workshop for evaluation of CIMAher® in patients with high grade glioma of malignancy was made in La Habana, Cuba.

The Center of Molecular Immunology and the National Coordination Center of Clinical Trials (CENCEC) developed the National Worksho ... (Read more)

Argentina trading partners obtained medical authorization of CIMAher (nimotuzumab) for the treatment of esophageal cancer in Argentina.

Argentina trading partners obtained medical authorization of CIMAher (nimotuzumab) for the treatment of esophageal cancer in Argen ... (Read more)

List all news

Professionals's opinion

Dra. Patricia Piedra Sierra - CIMAB S.A. Medical Manager

CIMAher (nimotuzumab) is a biological product, very well tolerated and with clear evidence of antitumor activity in patients with advanced tumors of h ... (Read more)

See all opinions